News
Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial
Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era ...
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...
GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...
Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...
Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.
In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...
Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.
A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials testing … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback